1. Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C,Thomassen MJ, et al. NO chemical events in the human airway during the immediateand late antigen-induced asthmatic response. Proc Natl Acad Sci USA. 2001;98:2622-7.

2. Dweik RA, Boggs PB, Erzurum SC, et al. Am J Respir Crit Care Med. 2011;184:602-15.

3. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax. 2006;61:817-27.

4. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163-73.

5. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138:682-92.

6. Ishizuka T, Hisada T, Kamide Y, Aoki H, Seki K, Honjo C. et al. The effects of concomitant GER D, dyspepsia,and rhinosinusitis on asthma symptoms and FeNO in asthmatic patients taking controller medications. Journal of Asthma and Allergy. 2014;7:131-9.

7. Pijnenburg MW, Hofhuis W, Hop WC, de Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax. 2005;60:215-8.

8. Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med. 2005;171:1077-82.

9. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitricoxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172:453-9.

10. Szefler SJ, Mitchell H, Sorkness CA, et al.Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008;372:1065-72.

11. Fritsch M, Uxa S, Horak F Jr, et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. Pediatr Pulmonol. 2006;41:855-62.

12. Petsky HL, Cates CJ, Lasserson TJ, Turner C, Kynaston JA. Original article: a systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67:199-208.

13. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-15.

14. Cutts R, Turner S. Longitudinal measurements of exhaled nitric oxide in children–what is a significant change in FENO? Pediatr Allergy Immunol. 2013;24:540-8.

15. Carvalho RM, Aarestrup BJ, da Silva FR, Goretti NC, Aarestrup FM. Fração exalada de óxido nítrico no diagnóstico e controle da asma em adolescentes. Braz J Allergy Immunol. 2014;2(1):28-34.

16. Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for Asthma Treatment Algorithm studies. Clin Exp Allergy. 2009;39:478-90.

17. Dressel H, de la Motte D, Reichert J, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med. 2008;102:962-9.

18. Smith AD, Cowan JO, Taylor DR. Exhaled nitric oxide levels in asthma: Personal best versus reference values. J Allergy Clin Immunol. 2009;124:714-8.

19. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide and blood eosinophils independently associate with wheeze and asthma events in NHANES subjects. J Allergy Clin Immunol. 2013;132:821-7.

20. Pavord ID, Bafadhel M. Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk. J Allergy Clin Immunol. 2013;132:828-9.

21. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-9.

22. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.

23. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in Persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66.

24. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804-11.

25. Payne D, Bush A. Phenotype-specific treatment of difficult asthma in children. Paediatr Respir Rev. 2004;5:116-23.

26. Fleming L, Tsartsali L, Wilson N, et al. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax. 2012;67:675-81.

27. Henderson AJ. Childhood asthma phenotypes in the twenty-first century. Breathe. 2014;10:101-8.